Nektar's IL-2 Impresses In Combination With Bristol's Opdivo

Nektar's IL-2 stimulating agonist NKTR-214 combines well with Bristol's Opdivo in Phase I PIVOT-02 study presented at SITC meeting in November.

T-cells attacking cancer_1200x675

The combination of Nektar Therapeutics' investigational interleukin-2 (IL-2) agent NKTR-214 with Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo has activity in lung, kidney cancer and melanoma, the partners said at the Society for Immunotherapy and Cancer meeting in November.

Nektar and Bristol presented positive early data for the combination of NKTR-214 and Opdivo in renal cell carcinoma, melanoma and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer